,,iii #aagth ,,congress #ast ,session ,s4 ,,res4 #ccf ,,in ,,the ,,senate ,,of ,,the ,,united ,,states ,august #d1 #bjba,mr4 ,kaine 7for himself and ,ms4 ,klobuchar7 submitted the following resolution2 which was referred to the ,committee on the ,judiciary ,,resolution ,designating ,september #ae1 #bjba1 as ,international ,myotonic ,dystrophy ,awareness ,day and supporting the goals and ideals of ,international ,myotonic ,dystrophy ,awareness ,day4 ,whereas myotonic dystrophy is a rare1 multi-systemic1 inherited disease that affects approximately #a in #b1ajj people and a total of #aej1jjj individuals in the ,united ,states2 ,whereas there are well over #a1jjj1jjj people living with myotonic dystrophy globally1 yet thousands of people do not know they have the disease and are in need of care2 ,whereas myotonic dystrophy is the most common form of adult muscular dystrophy and the symptoms of myotonic dystrophy become more severe with each generation2 ,whereas the disease is caused by mutations in the ,,dmpk gene and the ,,cnbp gene1 resulting in myotonic dystrophy type #a and myotonic dystrophy type #b1 respectively2 ,whereas those mutations prevent the ,,dmpk gene and the ,,cnbp gene from functioning properly1 impacting multiple body systems2 ,whereas the genetic mutations are autosomal dominant mutations1 where a single copy of the altered gene is sufficient to cause the disorder1 and affected individuals have a #ej percent chance of passing on the mutated gene to their children2 ,whereas1 through this inherited genetic anomaly1 individuals with myotonic dystrophy experience varied and complex symptoms1 including skeletal muscle problems1 excessive daytime sleepiness1 early cataracts and heart1 breathing1 digestive1 hormonal1 speech1 swallowing1 diabetic1 immune1 vision1 and cognitive difficulties2 ,whereas myotonic dystrophy is a highly variable and complicated disorder in which the younger an individual is when symptoms first appear1 the more severe symptoms are likely to be1 with progressively more severe symptoms occurring after the earlier symptoms are experienced2 ,whereas misdiagnoses of myotonic dystrophy have persisted for decades1 and delays in diagnosing myotonic dystrophy are common2 ,whereas there are currently no treatments for myotonic dystrophy approved by the ,food and ,drug ,administration2 ,whereas1 in #bjjg1 the ,myotonic ,dystrophy ,foundation was founded with a mission to enhance the quality of life of people living with myotonic dystrophy and to accelerate research focused on finding treatments and a cure2 ,whereas1 in #bjad1 ,congress reauthorized the ,paul ,d4 ,wellstone ,muscular ,dystrophy ,community ,assistance1 ,research1 and ,education ,amendments of #bjad 7,public ,law #aac-aff2 #db ,u4,s4,c4 #bja71 which increased muscular dystrophy research funding and public health surveillance activities1 including for myotonic dystrophy2 ,whereas1 in ,september #bjag1 recognizing the seriousness of myotonic dystrophy and the especially disabling impact of myotonic dystrophy on individuals with congenital myotonic dystrophy1 the ,social ,security ,administration added congenital myotonic dystrophy to the ,compassionate ,allowances program that allows individuals to quickly qualify for disability benefits1 including health insurance coverage2 ,whereas1 in #bjah1 ,congress added myotonic dystrophy to the list of eligible conditions for research funding under the ,peer ,reviewed ,medical ,research ,program of the ,department of ,defense1 which resulted in more than #f1jjj1jjj in new research awards2 ,whereas funding for myotonic dystrophy research supported by the ,national ,institutes of ,health remained flat between #bjaj and #bjbj with the agency awarding #bd1jjj1jjj in research grants in fiscal year #bjbj2 and ,whereas increased ,federal funding for myotonic dystrophy research will improve health outcomes1 reduce disability1 and increase life expectancy for individuals living with myotonic dystrophy and holds great promise for helping individuals with similar genetic diseases3 ,now1 therefore1 be it ,that the ,senate-- 7#a7 designates ,september #ae1 #bjba1 as ,international ,myotonic ,dystrophy ,awareness ,day2 and 7#b7 supports the goals and ideals of ,international ,myotonic ,dystrophy ,awareness ,day1 including-- 7,a7 committing to promoting and advancing the health1 well-being1 and inherent dignity of all children and adults with myotonic dystrophy2 7,b7 supporting the advancement of scientific and medical myotonic dystrophy research at the ,national ,institutes of ,health and as part of the ,peer ,reviewed ,medical ,research ,program of the ,department of ,defense2 7,c7 fostering biopharmaceutical innovation that will lead to treatments approved by the ,food and ,drug ,administration and eventually a cure for myotonic dystrophy2 7,d7 advancing programs and policies that assist individuals disabled by myotonic dystrophy and the caregivers of those individuals2 and 7,e7 encouraging awareness and education of myotonic dystrophy among patients1 caregivers1 clinicians1 and researchers4